Mona S El-Raziky
Overview
Explore the profile of Mona S El-Raziky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mogahed E, El-Karaksy H, Abdullatif H, Yasin N, Nagy A, Abdel Alem S, et al.
J Pediatr
. 2021 Feb;
233:126-131.
PMID: 33577805
Objectives: To assess the degree of liver stiffness using transient elastography in Egyptian children infected with hepatitis C virus (HCV) at baseline and 1 year after achievement of sustained virologic...
2.
Mogahed E, Ghita H, El-Raziky M, El-Sherbini S, Meshref D, El-Karaksy H
Dig Liver Dis
. 2020 Jun;
52(8):889-894.
PMID: 32527656
Background: Hepatic dysfunction has a significant role in intensive care unit patients' morbidity and mortality. Aim: To study the frequency, risk factors and outcome of secondary hepatic dysfunction in children...
3.
Mogahed E, Sayed A, Khalifa S, El-Hennawy A, El-Raziky M
Eur J Pediatr
. 2020 Jan;
179(5):719-726.
PMID: 31897838
This study aimed to detect etiologies and histopathological features of non-alcoholic fatty liver disease (NAFLD) in Egyptian children < 10 years from hepatologist perspectives. Infants and children below 10 years...
4.
El-Karaksy H, Mogahed E, Abdullatif H, Ghobrial C, El-Raziky M, El-Koofy N, et al.
J Pediatr Gastroenterol Nutr
. 2018 Sep;
67(5):626-630.
PMID: 30216203
Objectives: Recently, direct acting antivirals (DAAs), sofosbuvir (SOF) combined with ledipasvir (LED), were approved for treatment of hepatitis C virus (HCV)-infected children 12 years of age and older or weighting...
5.
El-Karaksy H, Mogahed E, El-Raziky M, Saleh D, Besheer M, Mubarak S
J Interferon Cytokine Res
. 2015 Sep;
36(1):1-8.
PMID: 26406390
Combined treatment with pegylated interferon (PEG-IFN)-α2b and ribavirin (RBV) is the only currently approved treatment for hepatitis C virus (HCV) infection in children. The aim of this study was to...
6.
El-Karaksy H, El-Raziky M, Fouad H, Anwar G, El-Mougy F, El-Koofy N, et al.
Diabetes Metab Syndr
. 2014 Dec;
9(2):114-9.
PMID: 25470627
Objective: The aim of the present study was to determine the association between insulin resistance (IR) and both non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) in a group...
7.
El-Karaksy H, El-Raziky M, Anwar G, Mogahed E
J Pediatr Endocrinol Metab
. 2014 Aug;
28(1-2):195-200.
PMID: 25153581
Aim: To determine the individual fasting tolerance for patients with glycogen storage disease type III (GSD III) and to assess their linear growth velocity after tailoring of dose intervals of...
8.
Naghi S, Abdel-Ghaffar T, El-Karaksy H, Abdel-Aty E, El-Raziky M, Allam A, et al.
World J Gastroenterol
. 2014 May;
20(16):4681-91.
PMID: 24782620
Aim: To investigate the safety and efficacy of a Hansenula-derived PEGylated (polyethylene glycol) interferon (IFN)-alpha-2a (Reiferon Retard) plus ribavirin customized regimen in treatment-naïve and previously treated (non-responders and relapsers) Egyptian...
9.
El-Raziky M, El-Hawary M, Salama K, El-Hennawy A, Helmy H, Fahmy M, et al.
Arab J Gastroenterol
. 2012 May;
13(1):1-3.
PMID: 22560816
Background And Study Aims: Mass compulsory HBV vaccination was applied in Egypt in 1992. The first dose of vaccine is administered at 2 months of age and routine screening of...
10.
Abdelwahab M, El-Raziky M, Kaddah N, Abou-Elew H
Ann Saudi Med
. 2012 Feb;
32(2):200-2.
PMID: 22366833
Background And Objective: The risk of blood-borne infections, especially hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection still remains in developing countries among children receiving blood products as...